Campbell & CO Investment Adviser LLC Sells 19,545 Shares of Collegium Pharmaceutical, Inc. $COLL

Campbell & CO Investment Adviser LLC decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 50.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 19,207 shares of the specialty pharmaceutical company’s stock after selling 19,545 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Collegium Pharmaceutical were worth $672,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in COLL. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares during the period. Emerald Advisers LLC grew its holdings in shares of Collegium Pharmaceutical by 1.3% in the 2nd quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock valued at $24,766,000 after acquiring an additional 11,074 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Collegium Pharmaceutical by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock valued at $23,075,000 after acquiring an additional 14,709 shares in the last quarter. Millennium Management LLC raised its holdings in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Collegium Pharmaceutical by 13.8% in the 2nd quarter. Bank of America Corp DE now owns 514,807 shares of the specialty pharmaceutical company’s stock valued at $15,223,000 after buying an additional 62,274 shares during the last quarter.

Collegium Pharmaceutical Trading Up 4.6%

Shares of NASDAQ COLL opened at $47.70 on Wednesday. The firm has a 50 day moving average price of $47.20 and a two-hundred day moving average price of $39.43. The stock has a market cap of $1.51 billion, a P/E ratio of 29.63 and a beta of 0.60. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $50.79. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 EPS for the quarter, beating analysts’ consensus estimates of $1.89 by $0.36. The company had revenue of $209.36 million for the quarter, compared to analyst estimates of $191.25 million. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The company’s quarterly revenue was down 18.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.61 EPS. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analyst Upgrades and Downgrades

COLL has been the subject of several recent analyst reports. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a research note on Wednesday, January 7th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price (up previously from $46.00) on shares of Collegium Pharmaceutical in a research report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Insiders Place Their Bets

In other news, Director Rita J. Balice-Gordon sold 3,650 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total value of $1,215,900.00. Following the completion of the transaction, the chief financial officer owned 126,667 shares in the company, valued at approximately $5,133,813.51. This represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 51,250 shares of company stock worth $2,235,352. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.